NCT05645627

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

A Phase Ⅲ, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of IBI112 in Different Dose Regimens for the Treatment of Subjects With Moderate-to-severe Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 500 (actual)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	IBI112	IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48
DRUG	placebo /IBI112	placebo by subcutaneous injection cross over IBI112 by subcutaneous injection at week 16 through week 48
DRUG	IBI112	IBI112 by subcutaneous injection through week 16 ,and then will receive Dose 3 IBI112 by subcutaneous injection through week 48

Timeline

• Start date: 2023-02-10
• Primary completion: 2023-08-09
• Completion: 2024-08-01
• First posted: 2022-12-09
• Last updated: 2024-10-29

Locations

1 site across 1 country: China